Conference Day 2

Explore our agenda to see all sessions, timings, and full speaker details for the 2021 Gastrointestinal Cancer Drug Development Summit.

This event has now run.

8:00 am Online Networking Coffee

8:50 am Chair’s Opening Remarks

  • Umberto Malapelle Chief Supervisor, Predictive Molecular Pathology Laboratory, Department of Public Health, University of Naples Federico II

Rational Drug Development to Address Tumor Resistance Mechanisms

9:00 am FGFR2 Fusions: Addressing Clinically Relevant Secondary Mutations

Synopsis

  • FGFR2 alterations are known oncogenic drivers in intrahepatic cholangiocarcinoma (iCCA) with fusions or rearrangements detected in > 10% of patients
  • Preclinical studies with KIN-3248, an irreversible pan-FGFR inhibitor, demonstrate inhibition across the full spectrum of clinically relevant FGFR2 secondary resistance mutations observed in iCCA
  • Duration of response may be improved by targeting known FGFR2 secondary resistance mechanisms to approved FGFR inhibitors and will be explored in clinical studies of KIN-3248 in FGFR2-altered iCCA

9:30 am Targeting RAS Mutant GI Cancers – Treatment Strategies and Resistance Mechanisms

Synopsis

  • Unmet medical need in RAS mutant GI cancers
  • RAS(ON) Targeted Therapies for RAS mutant GI cancers: mutantselective and RASMulti inhibitors
  • Application of biomarker-driven combination strategies

10:00 am Morning Networking Break

Developing a Clinical Program for ADCs to Progress Your Candidate

10:30 am Developing ADCs For HER2-Positive Gastric Cancer: Pivotal Research Efforts Made in GI Cancers & The Next Steps For Novel Approaches

  • Nataliya Uboha Faculty Leader for Cancer Therapy Discovery & Development/Phase I Program, University of Wisconsin-Madison

11:00 am Precision Chemo Radiotherapy Using ADCs in GI Cancers

Synopsis

  • Advantages of concurrent chemo-radiotherapy
  • Specificity of the target
  • Careful selection of drug, impact of bystander effect

11:30 am Online Networking Lunch

Building an Effective Clinical Trial Program in GI Cancer

12:30 pm Strategies to Optimize Timely Patient Identification & Accrual for Clinical Trials

  • Afsaneh Barzi Associate Professor of Medical Oncology & Chief Medical Advisor, City of Hope-Director of Employer Health & Access-Hope Cardiff Oncology

Synopsis

  • Heterogeneity populations and outcomes of the diseases in the GI portfolio
  • Patient experience with cancer and its impact on the treatment
  • Provider experience with the patient population and treatment selection

1:00 pm Can Technology Make Clinical Trials More Diverse & Representative?

  • Muhammad Shaalan Beg Associate Professor & Assistant Director - Gastrointestinal Medical & Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern

Synopsis

  • The current clinical trial infrastructure does not serve our patients well
  • Advances in technology and virtual care are poised to change how we perform clinical trials
  • Pancreatic cancer and other GI cancers are the ideal model to test a new paradigm in clinical trials

1:30 pm Afternoon Networking Break

Optimizing Clinical Practice, Early Detection & Precision Oncology to Improve Patient Outlook

2:00 pm Tracking Quality in GI Cancer Screening Programs for Early Detection & Improved Outcomes

  • David A. Leiman Assistant Professor of Medicine, Director, Esophageal Research & Quality Division of Gastroenterology, Duke University Medical Center Duke Clinical Research Institute

2:30 pm BloodPAC Consortium: Accelerating Development, Approval & Accessibility

Synopsis

  • Developing BloodPAC: a collaboration to compete and accelerate progress in the liquid biopsy field
  • Evidence generation: defining standards and guidelines to benefit stakeholders
  • BloodPAC data commons: aggregating data to support standards for the community
  • Stakeholder engagement: Where do we go from here? Reimbursement and accessibillity for patient benefit

3:00 pm Chair’s Closing Remarks & End Of Conference